Costs and quality of life in multiple sclerosis patients with spasticity

The socioeconomic consequences of optic neuritis with and without multiple sclerosis: a controlled national study

(2012) P. Jennum et al.   ACTA NEUROLOGICA SCANDINAVICA

Validation of the multiple sclerosis international quality of life (MusiQoL) questionnaire in Norwegian patients

(2011) A. G. Beiske et al.   ACTA NEUROLOGICA SCANDINAVICA

Cumulative impact of comorbidity on quality of life in MS

(2011) R. A. Marrie et al.   ACTA NEUROLOGICA SCANDINAVICA

Cost of disorders of the brain in Europe 2010

(2011) Anders Gustavsson et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

The socioeconomic consequences of multiple sclerosis: A controlled national study

(2011) Poul Jennum et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study

(2011) Rafael Arroyo et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Validity, reliability, and clinical importance of change in a 0—10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial

(2008) John T. Farrar et al.   CLINICAL THERAPEUTICS

Multiple Sclerosis in the UK

(2008) Paul McCrone et al.   PHARMACOECONOMICS